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Abstract  
Migration Stimulating Factor (MSF) is a 70kDa truncated isoform of fibronectin (FN).  
Unlike FN, MSF is not a matrix molecule but a soluble factor which exhibits a range of 
potent cytokine-like bioactivities not displayed by full-length FN.  Two isoforms of human 
MSF (MSF+aa and MSF-aa), as well as murine Migration Stimulating Factor (mMSF) have 
been cloned.  In this communication we report the characterisation of various polyclonal and 
monoclonal antibodies to human and murine MSF.  In particular: 
(i) Specific MSF-identification antibodies that recognise both MSF+aa and MSF-aa; 
(ii) Specific mMSF-identification antibodies; 
(iii) Identification antibodies that recognise MSF-aa but not MSF+aa; 
(iv) MSF-function-neutralising antibodies that recognise MSF+aa, MSF-aa, mMSF 
and the gelatin-binding domain of FN/MSF (Gel-BD) but not full-length FN. 
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Description of the antigens:  
Fibronectin (FN) is a modular glycoprotein consisting of the following functional domains: 
Hep 1/Fib-1 (N-terminal low affinity binding to heparin and fibrin), Gel-BD (binding to 
gelatin/collagen), Cell-BD (RGD-mediated binding to integrins), Hep-2 (high affinity heparin 
binding) and Fib-2 (C-terminal  fibrin binding site).  Each functional domain is composed of 
a different number of three possible homology modules, called type I, II and III (Fig 1). 
Human Migration Stimulating Factor (referred to as MSF) is a 70kDa truncated isoform of 
FN.  MSF RNA is generated from the fibronectin gene by a two-stage processing mechanism.  
In the first stage, an MSF-specific primary transcript is generated from the fibronectin gene 
by read-through of intron 12, separating exons III-1a and III-1b. This is followed by intra-
intronic cleavage to produce a 5.9 kb MSF pre-message that remains sequestered within the 
nucleus, where it is rapidly degraded.  In cells that express MSF protein a second stage takes 
place, whereby the intron-derived 3’ UTR of the pre-message is cleaved a second time to 
produce a 2.1 kb mature MSF message.  This has a shorter (195bp) intron-derived 3’ 
sequence containing a 30bp in-frame coding sequence (immediately contiguous with exon 
III-1a), followed by a 165bp 3’-UTR containing several in-frame stop codons and a 
cleavage/polyadenylation signal.  The mature message is rapidly exported to the cytoplasm 
for translation [Schor et al, 2003; Kay et al, 2005].  Therefore, MSF is identical to the N 
terminus of full-length fibronectin, up to and including the amino acid sequence coded by 
exon III-1a, with the addition of an MSF-unique (intron-coded) 10 amino acid C-terminus: 
VSIPPRNLGY [Schor et al, 2003; Kay et al, 2005] (Fig 1).  
 
FN is a major component of the extracellular matrix.  Unlike FN, MSF is a monomer and is 
not a matrix molecule but a soluble factor which exhibits a range of cytokine-like 
bioactivities, including the stimulation of cell migration and angiogenesis.  The motogenic 
activity of MSF is mediated by the IGD motifs, present in modules I3, I5, I7 and I9 of the 
Gel-BD domain and, in some cases, by the HEEGH motif present in module I8  [Schor et al, 
1999,  2003; Houard et al, 2005; Millard et al, 2007] (Fig 1, Fig 2). The bioactivities of MSF 
are not expressed by full-length fibronectin, due to steric hindrance [Millard et al, 2007; 
Vakonakis et al 2009].  
Two isoforms of MSF (referred to as MSF) have been cloned.  Both contain the same unique 
10 amino acid C-terminus as well as same bioactive IGD and HEEGH amino acid motifs.  
The two isoforms differ solely in terms of a 45bp deletion in exon II-1 and are consequently 
referred to as MSF+aa and MSF-aa to indicate the retention or deletion of a 15 amino acid 
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sequence in module II-1 (Fig 1 and Fig 2).   The term MSF or total MSF will be employed to 
denote both isoforms.   
 
We have isolated and cloned a murine MSF (mMSF) transcript by PCR.  This is homologous 
to its human counterpart, consisting of the 5-terminus of mouse FN, up to and including exon 
III-1a, and terminating in a unique 3’coding sequence derived from the intron separating 
exons III-1a and -1b.  The 3’UTR ends in a polyA tail.  mMSF protein consequently has a 
molecular mass of 70kDa and terminates in a unique 12 amino acid C-terminus: 
VSNSSAALDSDP (Fig 3).  The murine FN coding sequence is over 90% homologous to 
human FN; the four IGD motifs and the HEEGH motif are similarly located in modules I3, 
I5, I7, I9 and I8, respectively.  However, there is no significant homology between the human 
and mouse intron-derived C-terminal MSF-unique peptides.    
Eukaryotic and prokaryotic recombinant MSF and mMSF were produced as described [Schor 
et al 2003].  
We have raised polyclonal (Pab) and monoclonal (Mab) antibodies to human and murine 
MSF.  The peptides used as antigens to raise these antibodies and an overview of the results 
obtained are shown in Table 1.  The antibodies were characterised by ELISA, 
immunoblotting, IHC and their ability to abrogate or remove MSF/mMSF bioactivity [Schor 
et al 2003, 2012].  As expected, different antibodies were useful for certain techniques and 
not for others.   
 
Production of antibodies  
To be completed  
 
Characterisation of VSI antibodies  
To be completed  
 
Conclusions: VSI are MSF-specific identification antibodies that recognise the unique 10-mer 
C-terminal sequence of MSF+aa and MSF-aa; that is, total MSF.  
 
Characterisation of TYN antibodies  
To be completed  
 
Conclusions: TYN are identification antibodies that recognise MSF-aa but not MSF+aa. 
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Characterisation of VSN antibodies  
To be completed  
 
Conclusions: VSN are mMSF-specific identification antibodies that recognise the unique 12-
mer C-terminal sequence of mMSF. 
 
Characterisation of pepQ antibodies  
To be completed  
 
Conclusions:  pepQ are MSF-function-neutralising antibodies that recognise MSF+aa, MSF-
aa, mMSF and Gel-BD but not FN.   
 
 
Methods 
To be completed  
 
1. ELISA 
2. Dot Blots  
3. Western Blots  
3. Immunohistochemistry (IHC) 
4. Cell migration 
5. Cell proliferation 
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Table 1.  Overview of the antibodies raised and results obtained.  
The peptides indicated were used as antigens to raise monoclonal (Mab) and polyclonal (Pab) 
antibodies.  
Peptide used as antigen Ab code Reactivity of Abs 
VSIPPRNLGY   
10 mer, MSF-unique C-terminus 
VSI Mab and Pab recognise MSF+aa 
and MSF-aa.  
Do not recognise FN, Gel-BD or 
Hep 1/Fib-1 domains. 
TYNDRTDSTTSNY  
13 mer, present in MSF-aa, II-1. In MSF+aa these 
amino acids are adjacent to the sequence deleted in 
MSF-aa (6 before and 7 after) 
TYN Mab and Pab recognise MSF-aa. 
Do not recognise MSF+aa, FN or 
Gel-BD 
VSNSSAALDSDP 
12 mer, mMSF-unique C-terminus  
VSN Pab recognise mMSF. Do not 
recognise MSF, FN or Gel-BD 
TNEGVMYRIGDQWDKQHDMGH 
21-mer, IGD-containing peptide in module I-7 
 
pepQ Mab recognise MSF+aa, MSF-aa 
and Gel-BD. 
Do not recognise FN. 
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Figure 1. The structure of fibronectin and MSF.  Fibronectin domains include: 
Hep 1/Fib-1 (N-terminal low affinity binding to heparin and fibrin), Gel-BD 
(binding to gelatin/collagen), Cell-BD (RGD-mediated binding to integrins), Hep-2 
(high affinity heparin binding) and Fib-2 (C-terminal fibrin binding site).  Each 
domain is composed of three possible homology modules, called type I, II and III.   
MSF is identical to the N terminus of fibronectin, up to and including the amino 
acid sequence coded by exon III-1a, with the addition of an MSF-unique (intron-
coded) 10 amino acid C-terminus. Two isoforms of MSF have been cloned.  These 
differ solely in terms of a 45bp deletion in exon II-1 and are consequently referred 
to as MSF+aa and MSF-aa to indicate the retention or deletion of a 15 amino acid 
sequence in module II-1. The location of IGD motifs (↓) and HEEGH motif (*) is 
indicated.  
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MSF+aa.  Accession number AJ535086 
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=Protein&id=27227743 
1   MLRGPGPGLL LLAVQCLGTA VPSTGASKSK RQAQQMVQPQ SPVAVSQSKP GCYDNGKHYQ 
61  INQQWERTYL GNALVCTCYG GSRGFNCESK PEAEETCFDK YTGNTYRVGD TYERPKDSMI 
121 WDCTCIGAGR GRISCTIANR CHEGGQSYKI GDTWRRPHET GGYMLECVCL GNGKGEWTCK 
181 PIAEKCFDHA AGTSYVVGET WEKPYQGWMM VDCTCLGEGS GRITCTSRNR CNDQDTRTSY 
241 RIGDTWRKKD NRGNLLQCIC TGNGRGEWKC ERHTSVQTTS SGSGPFTDVR AAVYQPQPHP 
301 QPPPYGHCVT DSGVVYSVGM QWLKTQGNKQ MLCTCLGNGV SCQETAVTQT YGGNSNGEPC 
361 VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS NYEQDQKYSF CTDHTVLVQT RGGNSNGALC 
421 HFPFLYNNHN YTDCTSEGRR DNMKWCGTTQ NYDADQKFGF CPMAAHEEIC TTNEGVMYRI 
481 GDQWDKQHDM GHMMRCTCVG NGRGEWTCIA YSQLRDQCIV DDITYNVNDT FHKRHEEGHM 
541 LNCTCFGQGR GRWKCDPVDQ CQDSETGTFY QIGDSWEKYV HGVRYQCYCY GRGIGEWHCQ 
601 PLQTYPSSSG PVEVFITETP SQPNSHPIQW NAPQPSHISK YILRWRPVSI PPRNLGY 
 
 
MSF-aa:  Accession number AJ276395 (15 amino acid deletion in module II-1) 
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=Protein&id=12053817 
 
1   MLRGPGPGLL LLAVQCLGTA VPSTGASKSK RQAQQMVQPQ SPVAVSQSKP GCYDNGKHYQ 
61  INQQWERTYL GNALVCTCYG GSRGFNCESK PEAEETCFDK YTGNTYRVGD TYERPKDSMI 
121 WDCTCIGAGR GRISCTIANR CHEGGQSYKI GDTWRRPHET GGYMLECVCL GNGKGEWTCK 
181 PIAEKCFDHA AGTSYVVGET WEKPYQGWMM VDCTCLGEGS GRITCTSRNR CNDQDTRTSY 
241 RIGDTWSKKD NRGNLLQCIC TGNGRGEWKC ERHTSVQTTS SGSGPFTDVR AAVYQPQPHP 
301 QPPPYGHCVT DSGVVYSVGM QWLKTQGNKQ MLCTCLGNGV SCQETAVTQT YGGNSNGEPC 
361 VLPFTYNDRT DSTTSNYEQD QKYSFCTDHT VLVQTRGGNS NGALCHFPFL YNNHNYTDCT 
421 SEGRRDNMKW CGTTQNYDAD QKFGFCPMAA HEEICTTNEG VMYRIGDQWD KQHDMGHMMR 
481 CTCVGNGRGE WTCIAYSQLR DQCIVDDITY NVNDTFHKRH EEGHMLNCTC FGQGRGRWKC 
541 DPVDQCQDSE TGTFYQIGDS WEKYVHGVRY QCYCYGRGIG EWHCQPLQTY PSSSGPVEVF 
601 ITETPSQPNS HPIQWNAPQP SHISKYILRW RPVSIPPRNL GY 
 
 
 
 
 
 
 
 
 
  
Figure 2. MSF+aa and MSF-aa protein sequences.  The sequences highlighted are: MSF-
unique decamer in red (sequence MSF does not share with FN).  MSF 15 amino acid region 
present in MSF+aa and absent in MSF-aa in blue.  IGD and HEEGH motifs in purple.  
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     1   M  L  R  G  P  G  P  G  R  L  L  L  L  A  V  L  C  L  G  T  
     1  ATGCTCAGGGGTCCGGGACCCGGGCGGCTGCTGCTGCTGGCAGTCCTGTGCCTGGGGACC 
    21   S  V  R  C  T  E  A  G  K  S  K  R  Q  A  Q  Q  I  V  Q  P  
    61  TCGGTGCGCTGCACCGAAGCCGGGAAGAGCAAGAGGCAGGCTCAGCAAATCGTGCAGCCT 
    41   Q  S  P  V  A  V  S  Q  S  K  P  G  C  F  D  N  G  K  H  Y  
   121  CAATCCCCGGTGGCTGTCAGTCAGAGCAAGCCTGGCTGTTTTGACAATGGGAAGCACTAT 
    61   Q  I  N  Q  Q  W  E  R  T  Y  L  G  N  A  L  V  C  T  C  Y  
   181  CAGATAAATCAGCAGTGGGAACGGACCTACCTAGGCAACGCCCTGGTTTGTACCTGCTAT 
    81   G  G  S  R  G  F  N  C  E  S  K  P  E  P  E  E  T  C  F  D  
   241  GGAGGAAGCCGGGGTTTTAACTGCGAGAGCAAGCCTGAGCCTGAAGAGACTTGCTTTGAC 
   101   K  Y  T  G  N  T  Y  K  V  G  D  T  Y  E  R  P  K  D  S  M  
   301  AAATACACTGGGAACACTTACAAAGTGGGTGACACTTATGAGCGCCCTAAAGATTCCATG 
   121   I  W  D  C  T  C  I  G  A  G  R  G  R  I  S  C  T  I  A  N  
   361  ATCTGGGACTGTACCTGCATCGGGGCTGGGAGAGGCAGGATCAGCTGTACCATTGCAAAT 
   141   R  C  H  E  G  G  Q  S  Y  K  I  G  D  K  W  R  R  P  H  E  
   421  CGCTGCCATGAAGGGGGTCAGTCCTACAAGATTGGCGACAAGTGGAGGAGGCCACATGAG 
   161   T  G  G  Y  M  L  E  C  L  C  L  G  N  G  K  G  E  W  T  C  
   481  ACTGGTGGCTACATGTTAGAGTGTCTGTGTCTGGGAAATGGAAAAGGGGAATGGACCTGC 
   181   K  P  I  A  E  K  C  F  D  H  A  A  G  T  S  Y  V  V  G  E  
   541  AAACCTATAGCTGAGAAGTGTTTTGATCATGCTGCTGGGACGTCCTACGTCGTGGGGGAG 
   201   T  W  E  K  P  Y  Q  G  W  M  M  V  D  C  T  C  L  G  E  G  
   601  ACCTGGGAAAAGCCCTACCAAGGCTGGATGATGGTGGACTGTACTTGTCTAGGCGAAGGC 
   221   N  G  R  I  T  C  T  S  R  N  R  C  N  D  Q  D  T  R  T  S  
   661  AATGGACGCATCACCTGTACCTCCAGAAACAGATGCAACGATCAGGACACCCGGACATCC 
   241   Y  R  I  G  D  T  W  S  K  K  D  N  R  G  N  L  L  Q  C  V  
   721  TATAGGATTGGAGACACGTGGAGCAAGAAGGACAACCGAGGAAACCTGCTTCAGTGTGTC 
   261   C  T  G  N  G  R  G  E  W  K  C  E  R  H  A  L  Q  S  A  S  
   781  TGCACAGGCAATGGCAGAGGGGAGTGGAAGTGTGAGCGACATGCTCTACAAAGTGCTTCA 
   281   A  G  S  G  S  F  T  D  V  R  T  A  I  Y  Q  P  Q  T  H  P  
   841  GCCGGATCTGGCTCCTTCACTGATGTCCGAACAGCTATTTACCAACCGCAGACTCACCCC 
   301   Q  P  A  P  Y  G  H  C  V  T  D  S  G  V  V  Y  S  V  G  M  
   901  CAGCCCGCTCCCTACGGCCACTGTGTCACCGACAGTGGTGTGGTCTACTCTGTGGGAATG 
   321   Q  W  L  K  S  Q  G  N  K  Q  M  L  C  T  C  L  G  N  G  V  
   961  CAGTGGCTGAAGTCGCAAGGAAACAAGCAAATGCTGTGCACGTGCCTGGGCAATGGCGTC 
   341   S  C  Q  E  T  A  V  T  Q  T  Y  G  G  N  S  N  G  E  P  C  
  1021  AGCTGCCAGGAGACAGCCGTGACCCAGACTTATGGTGGCAATTCAAACGGGGAGCCCTGT 
   361   V  L  P  F  T  Y  N  G  R  T  F  Y  S  C  T  T  E  G  R  Q  
  1081  GTCCTCCCGTTCACCTACAACGGTAGGACCTTCTATTCCTGCACCACCGAAGGGCGGCAA 
   381   D  G  H  L  W  C  S  T  T  S  N  Y  E  Q  D  Q  K  Y  S  F  
  1141  GACGGACATCTGTGGTGTAGCACAACTTCCAATTACGAACAAGACCAGAAGTATTCCTTC 
   401   C  T  D  H  A  V  L  V  Q  T  R  G  G  N  S  N  G  A  L  C  
  1201  TGCACAGACCATGCGGTTTTGGTTCAGACTCGAGGCGGAAATTCCAATGGTGCTCTGTGC 
   421   H  F  P  F  L  Y  N  N  R  N  Y  T  D  C  T  S  E  G  R  R  
  1261  CACTTCCCCTTCCTGTACAACAACCGGAATTACACCGACTGTACTTCTGAGGGTCGCAGG 
   441   D  N  M  K  W  C  G  T  T  Q  N  Y  D  A  D  Q  K  F  G  F  
  1321  GACAACATGAAATGGTGCGGCACCACCCAGAACTACGATGCCGATCAGAAGTTTGGATTC 
   461   C  P  M  A  A  H  E  E  I  C  T  T  N  E  G  V  M  Y  R  I  
  1381  TGCCCAATGGCTGCCCACGAGGAGATCTGCACAACCAATGAAGGGGTCATGTATCGCATT 
   481   G  D  Q  W  D  K  Q  H  D  L  G  H  M  M  R  C  T  C  V  G  
  1441  GGGGATCAGTGGGATAAGCAGCATGACCTGGGCCACATGATGAGGTGCACGTGTGTGGGG 
   501   N  G  R  G  E  W  A  C  I  P  Y  S  Q  L  R  D  Q  C  I  V  
  1501  AACGGTCGTGGAGAATGGGCCTGCATCCCCTACTCCCAGCTCCGAGACCAGTGCATCGTT 
   521   D  D  I  T  Y  N  V  N  D  T  F  H  K  R  H  E  E  G  H  M  
  1561  GATGACATTACTTACAATGTGAACGACACGTTCCACAAGCGTCACGAGGAGGGACATATG 
   541   L  N  C  T  C  F  G  Q  G  R  G  R  W  K  C  D  P  I  D  Q  
  1621  CTGAACTGTACCTGCTTTGGTCAGGGCCGGGGCAGATGGAAGTGTGACCCCATTGACCAG 
   561   C  Q  D  S  E  T  R  T  F  Y  Q  I  G  D  S  W  E  K  F  V  
  1681  TGCCAAGATTCAGAGACCCGGACATTTTACCAGATTGGTGACTCCTGGGAGAAGTTTGTG 
   581   H  G  V  R  Y  Q  C  Y  C  Y  G  R  G  I  G  E  W  H  C  Q  
  1741  CATGGTGTCCGATACCAGTGTTACTGCTACGGCCGTGGCATCGGGGAGTGGCACTGTCAA 
   601   P  L  Q  T  Y  P  G  T  T  G  P  V  Q  V  I  I  T  E  T  P  
  1801  CCTCTGCAGACCTACCCAGGCACAACTGGACCTGTCCAAGTAATTATCACGGAGACCCCC 
   621   S  Q  P  N  S  H  P  I  Q  W  N  A  P  E  P  S  H  I  T  K  
  1861  AGCCAGCCCAATTCCCACCCCATCCAGTGGAATGCCCCGGAGCCTTCACACATCACCAAG 
   641   Y  I  L  R  W  R  P  V  S  N  S  S  A  A  L  D  S  D  P  -  
  1921  TACATTCTCAGATGGAGACCTGTGAGTAATAGCTCCGCAGCCTTGGACTCTGACCCCTGA 
 
 
 
 
 
 
 
Figure 3.  Murine MSF protein and nucleotide sequences.  The protein 
sequences highlighted are: MSF-unique decamer in red (sequence mMSF does not 
share with mouse FN).  mMSF 15 amino acid region absent in MSF-aa in blue.  
IGD and HEEGH motifs in purple. 
